Health-Chem Corporation
Health-Chem Corporation (HCLC) Stock Competitors & Peer Comparison
See (HCLC) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Diagnostics & Research Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| HCLC | $0.00 | +0.00% | 74K | N/A | N/A | N/A |
| GNTLF | $1.00 | +0.00% | 3.7T | -16.67 | -$0.06 | N/A |
| LZAGY | $67.43 | -0.15% | 46.6B | 51.52 | $1.29 | +0.63% |
| LZAGF | $690.00 | +1.31% | 46.6B | 52.90 | $12.92 | +0.70% |
| WUXAY | $13.32 | +5.25% | 38.2B | 19.40 | $0.67 | +2.49% |
| WUXIF | $7.34 | +0.00% | 35.5B | 23.39 | $0.54 | +1.45% |
| BMXMF | $144.20 | +0.00% | 17.6B | 35.43 | $4.21 | +0.66% |
| ERFSF | $76.70 | -0.39% | 13.5B | 28.83 | $2.63 | +0.90% |
| SKHHY | $18.28 | +0.83% | 8.9B | 24.34 | $0.74 | +3.72% |
| SKHCF | $18.39 | -2.08% | 8.4B | 23.04 | $0.74 | +4.12% |
Stock Comparison
HCLC vs GNTLF Comparison August 2025
HCLC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCLC stands at 74K. In comparison, GNTLF has a market cap of 3.7T. Regarding current trading prices, HCLC is priced at $0.00, while GNTLF trades at $1.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCLC currently has a P/E ratio of N/A, whereas GNTLF's P/E ratio is -16.67. In terms of profitability, HCLC's ROE is +0.11%, compared to GNTLF's ROE of -3.06%. Regarding short-term risk, HCLC and GNTLF have similar daily volatility (0.00).Check GNTLF's competition here
HCLC vs LZAGY Comparison August 2025
HCLC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCLC stands at 74K. In comparison, LZAGY has a market cap of 46.6B. Regarding current trading prices, HCLC is priced at $0.00, while LZAGY trades at $67.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCLC currently has a P/E ratio of N/A, whereas LZAGY's P/E ratio is 51.52. In terms of profitability, HCLC's ROE is +0.11%, compared to LZAGY's ROE of +0.07%. Regarding short-term risk, HCLC is less volatile compared to LZAGY. This indicates potentially lower risk in terms of short-term price fluctuations for HCLC.Check LZAGY's competition here
HCLC vs LZAGF Comparison August 2025
HCLC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCLC stands at 74K. In comparison, LZAGF has a market cap of 46.6B. Regarding current trading prices, HCLC is priced at $0.00, while LZAGF trades at $690.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCLC currently has a P/E ratio of N/A, whereas LZAGF's P/E ratio is 52.90. In terms of profitability, HCLC's ROE is +0.11%, compared to LZAGF's ROE of +0.07%. Regarding short-term risk, HCLC is less volatile compared to LZAGF. This indicates potentially lower risk in terms of short-term price fluctuations for HCLC.Check LZAGF's competition here
HCLC vs WUXAY Comparison August 2025
HCLC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCLC stands at 74K. In comparison, WUXAY has a market cap of 38.2B. Regarding current trading prices, HCLC is priced at $0.00, while WUXAY trades at $13.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCLC currently has a P/E ratio of N/A, whereas WUXAY's P/E ratio is 19.40. In terms of profitability, HCLC's ROE is +0.11%, compared to WUXAY's ROE of +0.23%. Regarding short-term risk, HCLC is less volatile compared to WUXAY. This indicates potentially lower risk in terms of short-term price fluctuations for HCLC.Check WUXAY's competition here
HCLC vs WUXIF Comparison August 2025
HCLC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCLC stands at 74K. In comparison, WUXIF has a market cap of 35.5B. Regarding current trading prices, HCLC is priced at $0.00, while WUXIF trades at $7.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCLC currently has a P/E ratio of N/A, whereas WUXIF's P/E ratio is 23.39. In terms of profitability, HCLC's ROE is +0.11%, compared to WUXIF's ROE of +0.23%. Regarding short-term risk, HCLC and WUXIF have similar daily volatility (0.00).Check WUXIF's competition here
HCLC vs BMXMF Comparison August 2025
HCLC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCLC stands at 74K. In comparison, BMXMF has a market cap of 17.6B. Regarding current trading prices, HCLC is priced at $0.00, while BMXMF trades at $144.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCLC currently has a P/E ratio of N/A, whereas BMXMF's P/E ratio is 35.43. In terms of profitability, HCLC's ROE is +0.11%, compared to BMXMF's ROE of +0.11%. Regarding short-term risk, HCLC and BMXMF have similar daily volatility (0.00).Check BMXMF's competition here
HCLC vs ERFSF Comparison August 2025
HCLC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCLC stands at 74K. In comparison, ERFSF has a market cap of 13.5B. Regarding current trading prices, HCLC is priced at $0.00, while ERFSF trades at $76.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCLC currently has a P/E ratio of N/A, whereas ERFSF's P/E ratio is 28.83. In terms of profitability, HCLC's ROE is +0.11%, compared to ERFSF's ROE of +0.08%. Regarding short-term risk, HCLC is less volatile compared to ERFSF. This indicates potentially lower risk in terms of short-term price fluctuations for HCLC.Check ERFSF's competition here
HCLC vs SKHHY Comparison August 2025
HCLC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCLC stands at 74K. In comparison, SKHHY has a market cap of 8.9B. Regarding current trading prices, HCLC is priced at $0.00, while SKHHY trades at $18.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCLC currently has a P/E ratio of N/A, whereas SKHHY's P/E ratio is 24.34. In terms of profitability, HCLC's ROE is +0.11%, compared to SKHHY's ROE of +0.07%. Regarding short-term risk, HCLC is less volatile compared to SKHHY. This indicates potentially lower risk in terms of short-term price fluctuations for HCLC.Check SKHHY's competition here
HCLC vs SKHCF Comparison August 2025
HCLC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCLC stands at 74K. In comparison, SKHCF has a market cap of 8.4B. Regarding current trading prices, HCLC is priced at $0.00, while SKHCF trades at $18.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCLC currently has a P/E ratio of N/A, whereas SKHCF's P/E ratio is 23.04. In terms of profitability, HCLC's ROE is +0.11%, compared to SKHCF's ROE of +0.05%. Regarding short-term risk, HCLC and SKHCF have similar daily volatility (0.00).Check SKHCF's competition here
HCLC vs HNGZY Comparison August 2025
HCLC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCLC stands at 74K. In comparison, HNGZY has a market cap of 7.1B. Regarding current trading prices, HCLC is priced at $0.00, while HNGZY trades at $4.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCLC currently has a P/E ratio of N/A, whereas HNGZY's P/E ratio is 26.67. In terms of profitability, HCLC's ROE is +0.11%, compared to HNGZY's ROE of +0.02%. Regarding short-term risk, HCLC and HNGZY have similar daily volatility (0.00).Check HNGZY's competition here
HCLC vs DSRLF Comparison August 2025
HCLC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCLC stands at 74K. In comparison, DSRLF has a market cap of 5.9B. Regarding current trading prices, HCLC is priced at $0.00, while DSRLF trades at $107.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCLC currently has a P/E ratio of N/A, whereas DSRLF's P/E ratio is 26.90. In terms of profitability, HCLC's ROE is +0.11%, compared to DSRLF's ROE of +0.12%. Regarding short-term risk, HCLC and DSRLF have similar daily volatility (0.00).Check DSRLF's competition here
HCLC vs VIMGF Comparison August 2025
HCLC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCLC stands at 74K. In comparison, VIMGF has a market cap of 2.4B. Regarding current trading prices, HCLC is priced at $0.00, while VIMGF trades at $4.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCLC currently has a P/E ratio of N/A, whereas VIMGF's P/E ratio is 90.00. In terms of profitability, HCLC's ROE is +0.11%, compared to VIMGF's ROE of +0.03%. Regarding short-term risk, HCLC and VIMGF have similar daily volatility (0.00).Check VIMGF's competition here
HCLC vs MRCHF Comparison August 2025
HCLC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCLC stands at 74K. In comparison, MRCHF has a market cap of 1.3B. Regarding current trading prices, HCLC is priced at $0.00, while MRCHF trades at $23.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCLC currently has a P/E ratio of N/A, whereas MRCHF's P/E ratio is 68.18. In terms of profitability, HCLC's ROE is +0.11%, compared to MRCHF's ROE of +0.02%. Regarding short-term risk, HCLC and MRCHF have similar daily volatility (0.00).Check MRCHF's competition here
HCLC vs THOXF Comparison August 2025
HCLC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCLC stands at 74K. In comparison, THOXF has a market cap of 341M. Regarding current trading prices, HCLC is priced at $0.00, while THOXF trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCLC currently has a P/E ratio of N/A, whereas THOXF's P/E ratio is -37.50. In terms of profitability, HCLC's ROE is +0.11%, compared to THOXF's ROE of -1.09%. Regarding short-term risk, HCLC and THOXF have similar daily volatility (0.00).Check THOXF's competition here
HCLC vs EDTXF Comparison August 2025
HCLC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCLC stands at 74K. In comparison, EDTXF has a market cap of 172.5M. Regarding current trading prices, HCLC is priced at $0.00, while EDTXF trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCLC currently has a P/E ratio of N/A, whereas EDTXF's P/E ratio is -10.06. In terms of profitability, HCLC's ROE is +0.11%, compared to EDTXF's ROE of +0.79%. Regarding short-term risk, HCLC and EDTXF have similar daily volatility (0.00).Check EDTXF's competition here
HCLC vs AMCY Comparison August 2025
HCLC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCLC stands at 74K. In comparison, AMCY has a market cap of 171.3M. Regarding current trading prices, HCLC is priced at $0.00, while AMCY trades at $3.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCLC currently has a P/E ratio of N/A, whereas AMCY's P/E ratio is N/A. In terms of profitability, HCLC's ROE is +0.11%, compared to AMCY's ROE of N/A. Regarding short-term risk, HCLC and AMCY have similar daily volatility (0.00).Check AMCY's competition here
HCLC vs IDGXF Comparison August 2025
HCLC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCLC stands at 74K. In comparison, IDGXF has a market cap of 164.5M. Regarding current trading prices, HCLC is priced at $0.00, while IDGXF trades at $0.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCLC currently has a P/E ratio of N/A, whereas IDGXF's P/E ratio is 7.07. In terms of profitability, HCLC's ROE is +0.11%, compared to IDGXF's ROE of +0.19%. Regarding short-term risk, HCLC and IDGXF have similar daily volatility (0.00).Check IDGXF's competition here
HCLC vs NNGRF Comparison August 2025
HCLC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCLC stands at 74K. In comparison, NNGRF has a market cap of 164.3M. Regarding current trading prices, HCLC is priced at $0.00, while NNGRF trades at $12.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCLC currently has a P/E ratio of N/A, whereas NNGRF's P/E ratio is 60.75. In terms of profitability, HCLC's ROE is +0.11%, compared to NNGRF's ROE of -0.07%. Regarding short-term risk, HCLC and NNGRF have similar daily volatility (0.00).Check NNGRF's competition here
HCLC vs DIUXF Comparison August 2025
HCLC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCLC stands at 74K. In comparison, DIUXF has a market cap of 115.5M. Regarding current trading prices, HCLC is priced at $0.00, while DIUXF trades at $1.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCLC currently has a P/E ratio of N/A, whereas DIUXF's P/E ratio is 136.72. In terms of profitability, HCLC's ROE is +0.11%, compared to DIUXF's ROE of -0.04%. Regarding short-term risk, HCLC and DIUXF have similar daily volatility (0.00).Check DIUXF's competition here
HCLC vs ANPCF Comparison August 2025
HCLC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCLC stands at 74K. In comparison, ANPCF has a market cap of 100M. Regarding current trading prices, HCLC is priced at $0.00, while ANPCF trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCLC currently has a P/E ratio of N/A, whereas ANPCF's P/E ratio is -5.17. In terms of profitability, HCLC's ROE is +0.11%, compared to ANPCF's ROE of -0.66%. Regarding short-term risk, HCLC and ANPCF have similar daily volatility (0.00).Check ANPCF's competition here
HCLC vs CORBF Comparison August 2025
HCLC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCLC stands at 74K. In comparison, CORBF has a market cap of 95.1M. Regarding current trading prices, HCLC is priced at $0.00, while CORBF trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCLC currently has a P/E ratio of N/A, whereas CORBF's P/E ratio is 1.58. In terms of profitability, HCLC's ROE is +0.11%, compared to CORBF's ROE of +0.11%. Regarding short-term risk, HCLC and CORBF have similar daily volatility (0.00).Check CORBF's competition here
HCLC vs PFGTF Comparison August 2025
HCLC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCLC stands at 74K. In comparison, PFGTF has a market cap of 80.1M. Regarding current trading prices, HCLC is priced at $0.00, while PFGTF trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCLC currently has a P/E ratio of N/A, whereas PFGTF's P/E ratio is -4.93. In terms of profitability, HCLC's ROE is +0.11%, compared to PFGTF's ROE of -0.86%. Regarding short-term risk, HCLC and PFGTF have similar daily volatility (0.00).Check PFGTF's competition here
HCLC vs TIHE Comparison August 2025
HCLC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCLC stands at 74K. In comparison, TIHE has a market cap of 71.9M. Regarding current trading prices, HCLC is priced at $0.00, while TIHE trades at $1.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCLC currently has a P/E ratio of N/A, whereas TIHE's P/E ratio is 0.32. In terms of profitability, HCLC's ROE is +0.11%, compared to TIHE's ROE of +0.01%. Regarding short-term risk, HCLC and TIHE have similar daily volatility (0.00).Check TIHE's competition here
HCLC vs BIOGF Comparison August 2025
HCLC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCLC stands at 74K. In comparison, BIOGF has a market cap of 65.4M. Regarding current trading prices, HCLC is priced at $0.00, while BIOGF trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCLC currently has a P/E ratio of N/A, whereas BIOGF's P/E ratio is -0.67. In terms of profitability, HCLC's ROE is +0.11%, compared to BIOGF's ROE of +2.04%. Regarding short-term risk, HCLC and BIOGF have similar daily volatility (0.00).Check BIOGF's competition here
HCLC vs PCNEF Comparison August 2025
HCLC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCLC stands at 74K. In comparison, PCNEF has a market cap of 62M. Regarding current trading prices, HCLC is priced at $0.00, while PCNEF trades at $2.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCLC currently has a P/E ratio of N/A, whereas PCNEF's P/E ratio is -8.44. In terms of profitability, HCLC's ROE is +0.11%, compared to PCNEF's ROE of -0.09%. Regarding short-term risk, HCLC and PCNEF have similar daily volatility (0.00).Check PCNEF's competition here
HCLC vs LDXHF Comparison August 2025
HCLC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCLC stands at 74K. In comparison, LDXHF has a market cap of 48.7M. Regarding current trading prices, HCLC is priced at $0.00, while LDXHF trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCLC currently has a P/E ratio of N/A, whereas LDXHF's P/E ratio is -6.50. In terms of profitability, HCLC's ROE is +0.11%, compared to LDXHF's ROE of -0.60%. Regarding short-term risk, HCLC and LDXHF have similar daily volatility (0.00).Check LDXHF's competition here
HCLC vs CLIFF Comparison August 2025
HCLC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCLC stands at 74K. In comparison, CLIFF has a market cap of 44.1M. Regarding current trading prices, HCLC is priced at $0.00, while CLIFF trades at $0.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCLC currently has a P/E ratio of N/A, whereas CLIFF's P/E ratio is -2.87. In terms of profitability, HCLC's ROE is +0.11%, compared to CLIFF's ROE of -0.10%. Regarding short-term risk, HCLC and CLIFF have similar daily volatility (0.00).Check CLIFF's competition here
HCLC vs SNANF Comparison August 2025
HCLC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCLC stands at 74K. In comparison, SNANF has a market cap of 41.6M. Regarding current trading prices, HCLC is priced at $0.00, while SNANF trades at $0.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCLC currently has a P/E ratio of N/A, whereas SNANF's P/E ratio is -18.85. In terms of profitability, HCLC's ROE is +0.11%, compared to SNANF's ROE of -2.31%. Regarding short-term risk, HCLC and SNANF have similar daily volatility (0.00).Check SNANF's competition here
HCLC vs BIOQ Comparison August 2025
HCLC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCLC stands at 74K. In comparison, BIOQ has a market cap of 38.6M. Regarding current trading prices, HCLC is priced at $0.00, while BIOQ trades at $43.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCLC currently has a P/E ratio of N/A, whereas BIOQ's P/E ratio is 15.82. In terms of profitability, HCLC's ROE is +0.11%, compared to BIOQ's ROE of -0.06%. Regarding short-term risk, HCLC and BIOQ have similar daily volatility (0.00).Check BIOQ's competition here
HCLC vs BMKDF Comparison August 2025
HCLC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCLC stands at 74K. In comparison, BMKDF has a market cap of 27.2M. Regarding current trading prices, HCLC is priced at $0.00, while BMKDF trades at $0.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCLC currently has a P/E ratio of N/A, whereas BMKDF's P/E ratio is -25.90. In terms of profitability, HCLC's ROE is +0.11%, compared to BMKDF's ROE of +7.41%. Regarding short-term risk, HCLC is less volatile compared to BMKDF. This indicates potentially lower risk in terms of short-term price fluctuations for HCLC.Check BMKDF's competition here
HCLC vs IMMVF Comparison August 2025
HCLC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCLC stands at 74K. In comparison, IMMVF has a market cap of 22.6M. Regarding current trading prices, HCLC is priced at $0.00, while IMMVF trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCLC currently has a P/E ratio of N/A, whereas IMMVF's P/E ratio is -0.32. In terms of profitability, HCLC's ROE is +0.11%, compared to IMMVF's ROE of -5.30%. Regarding short-term risk, HCLC and IMMVF have similar daily volatility (0.00).Check IMMVF's competition here
HCLC vs PCHM Comparison August 2025
HCLC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCLC stands at 74K. In comparison, PCHM has a market cap of 21.7M. Regarding current trading prices, HCLC is priced at $0.00, while PCHM trades at $3.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCLC currently has a P/E ratio of N/A, whereas PCHM's P/E ratio is -0.02. In terms of profitability, HCLC's ROE is +0.11%, compared to PCHM's ROE of +0.53%. Regarding short-term risk, HCLC is less volatile compared to PCHM. This indicates potentially lower risk in terms of short-term price fluctuations for HCLC.Check PCHM's competition here
HCLC vs VILGF Comparison August 2025
HCLC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCLC stands at 74K. In comparison, VILGF has a market cap of 20.7M. Regarding current trading prices, HCLC is priced at $0.00, while VILGF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCLC currently has a P/E ratio of N/A, whereas VILGF's P/E ratio is -0.30. In terms of profitability, HCLC's ROE is +0.11%, compared to VILGF's ROE of N/A. Regarding short-term risk, HCLC and VILGF have similar daily volatility (0.00).Check VILGF's competition here
HCLC vs ANPCY Comparison August 2025
HCLC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCLC stands at 74K. In comparison, ANPCY has a market cap of 19.8M. Regarding current trading prices, HCLC is priced at $0.00, while ANPCY trades at $0.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCLC currently has a P/E ratio of N/A, whereas ANPCY's P/E ratio is -0.96. In terms of profitability, HCLC's ROE is +0.11%, compared to ANPCY's ROE of -0.66%. Regarding short-term risk, HCLC and ANPCY have similar daily volatility (0.00).Check ANPCY's competition here
HCLC vs MBGNF Comparison August 2025
HCLC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCLC stands at 74K. In comparison, MBGNF has a market cap of 17.3M. Regarding current trading prices, HCLC is priced at $0.00, while MBGNF trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCLC currently has a P/E ratio of N/A, whereas MBGNF's P/E ratio is -100.00. In terms of profitability, HCLC's ROE is +0.11%, compared to MBGNF's ROE of +0.35%. Regarding short-term risk, HCLC and MBGNF have similar daily volatility (0.00).Check MBGNF's competition here
HCLC vs VRCDF Comparison August 2025
HCLC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCLC stands at 74K. In comparison, VRCDF has a market cap of 15.1M. Regarding current trading prices, HCLC is priced at $0.00, while VRCDF trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCLC currently has a P/E ratio of N/A, whereas VRCDF's P/E ratio is -0.33. In terms of profitability, HCLC's ROE is +0.11%, compared to VRCDF's ROE of -0.76%. Regarding short-term risk, HCLC and VRCDF have similar daily volatility (0.00).Check VRCDF's competition here
HCLC vs IZOZF Comparison August 2025
HCLC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCLC stands at 74K. In comparison, IZOZF has a market cap of 14M. Regarding current trading prices, HCLC is priced at $0.00, while IZOZF trades at $0.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCLC currently has a P/E ratio of N/A, whereas IZOZF's P/E ratio is -7.71. In terms of profitability, HCLC's ROE is +0.11%, compared to IZOZF's ROE of +0.47%. Regarding short-term risk, HCLC is less volatile compared to IZOZF. This indicates potentially lower risk in terms of short-term price fluctuations for HCLC.Check IZOZF's competition here
HCLC vs ABDXF Comparison August 2025
HCLC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCLC stands at 74K. In comparison, ABDXF has a market cap of 13.6M. Regarding current trading prices, HCLC is priced at $0.00, while ABDXF trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCLC currently has a P/E ratio of N/A, whereas ABDXF's P/E ratio is -1.40. In terms of profitability, HCLC's ROE is +0.11%, compared to ABDXF's ROE of -0.48%. Regarding short-term risk, HCLC and ABDXF have similar daily volatility (0.00).Check ABDXF's competition here
HCLC vs PMSNF Comparison August 2025
HCLC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCLC stands at 74K. In comparison, PMSNF has a market cap of 13.3M. Regarding current trading prices, HCLC is priced at $0.00, while PMSNF trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCLC currently has a P/E ratio of N/A, whereas PMSNF's P/E ratio is -2.24. In terms of profitability, HCLC's ROE is +0.11%, compared to PMSNF's ROE of +0.71%. Regarding short-term risk, HCLC and PMSNF have similar daily volatility (0.00).Check PMSNF's competition here
HCLC vs JMPHF Comparison August 2025
HCLC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCLC stands at 74K. In comparison, JMPHF has a market cap of 11.4M. Regarding current trading prices, HCLC is priced at $0.00, while JMPHF trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCLC currently has a P/E ratio of N/A, whereas JMPHF's P/E ratio is -2.91. In terms of profitability, HCLC's ROE is +0.11%, compared to JMPHF's ROE of +0.43%. Regarding short-term risk, HCLC and JMPHF have similar daily volatility (0.00).Check JMPHF's competition here
HCLC vs MXDHF Comparison August 2025
HCLC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCLC stands at 74K. In comparison, MXDHF has a market cap of 8.6M. Regarding current trading prices, HCLC is priced at $0.00, while MXDHF trades at $0.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCLC currently has a P/E ratio of N/A, whereas MXDHF's P/E ratio is -0.12. In terms of profitability, HCLC's ROE is +0.11%, compared to MXDHF's ROE of -4.78%. Regarding short-term risk, HCLC and MXDHF have similar daily volatility (0.00).Check MXDHF's competition here
HCLC vs SQIDF Comparison August 2025
HCLC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCLC stands at 74K. In comparison, SQIDF has a market cap of 6.1M. Regarding current trading prices, HCLC is priced at $0.00, while SQIDF trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCLC currently has a P/E ratio of N/A, whereas SQIDF's P/E ratio is -0.37. In terms of profitability, HCLC's ROE is +0.11%, compared to SQIDF's ROE of +4.47%. Regarding short-term risk, HCLC is less volatile compared to SQIDF. This indicates potentially lower risk in terms of short-term price fluctuations for HCLC.Check SQIDF's competition here
HCLC vs AVCRF Comparison August 2025
HCLC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCLC stands at 74K. In comparison, AVCRF has a market cap of 5.9M. Regarding current trading prices, HCLC is priced at $0.00, while AVCRF trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCLC currently has a P/E ratio of N/A, whereas AVCRF's P/E ratio is -5.85. In terms of profitability, HCLC's ROE is +0.11%, compared to AVCRF's ROE of -0.42%. Regarding short-term risk, HCLC is less volatile compared to AVCRF. This indicates potentially lower risk in terms of short-term price fluctuations for HCLC.Check AVCRF's competition here
HCLC vs TDSGF Comparison August 2025
HCLC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCLC stands at 74K. In comparison, TDSGF has a market cap of 5.6M. Regarding current trading prices, HCLC is priced at $0.00, while TDSGF trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCLC currently has a P/E ratio of N/A, whereas TDSGF's P/E ratio is -2.78. In terms of profitability, HCLC's ROE is +0.11%, compared to TDSGF's ROE of -2.99%. Regarding short-term risk, HCLC and TDSGF have similar daily volatility (0.00).Check TDSGF's competition here
HCLC vs RNVA Comparison August 2025
HCLC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCLC stands at 74K. In comparison, RNVA has a market cap of 4.3M. Regarding current trading prices, HCLC is priced at $0.00, while RNVA trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCLC currently has a P/E ratio of N/A, whereas RNVA's P/E ratio is N/A. In terms of profitability, HCLC's ROE is +0.11%, compared to RNVA's ROE of +0.23%. Regarding short-term risk, HCLC and RNVA have similar daily volatility (0.00).Check RNVA's competition here
HCLC vs IDXG Comparison August 2025
HCLC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCLC stands at 74K. In comparison, IDXG has a market cap of 3.9M. Regarding current trading prices, HCLC is priced at $0.00, while IDXG trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCLC currently has a P/E ratio of N/A, whereas IDXG's P/E ratio is 3.14. In terms of profitability, HCLC's ROE is +0.11%, compared to IDXG's ROE of -1.19%. Regarding short-term risk, HCLC is less volatile compared to IDXG. This indicates potentially lower risk in terms of short-term price fluctuations for HCLC.Check IDXG's competition here
HCLC vs SLDX Comparison August 2025
HCLC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCLC stands at 74K. In comparison, SLDX has a market cap of 3.4M. Regarding current trading prices, HCLC is priced at $0.00, while SLDX trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCLC currently has a P/E ratio of N/A, whereas SLDX's P/E ratio is N/A. In terms of profitability, HCLC's ROE is +0.11%, compared to SLDX's ROE of +0.06%. Regarding short-term risk, HCLC and SLDX have similar daily volatility (0.00).Check SLDX's competition here
HCLC vs IBXXF Comparison August 2025
HCLC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCLC stands at 74K. In comparison, IBXXF has a market cap of 3M. Regarding current trading prices, HCLC is priced at $0.00, while IBXXF trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCLC currently has a P/E ratio of N/A, whereas IBXXF's P/E ratio is -0.50. In terms of profitability, HCLC's ROE is +0.11%, compared to IBXXF's ROE of +0.55%. Regarding short-term risk, HCLC and IBXXF have similar daily volatility (0.00).Check IBXXF's competition here
HCLC vs SZLSF Comparison August 2025
HCLC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCLC stands at 74K. In comparison, SZLSF has a market cap of 2.3M. Regarding current trading prices, HCLC is priced at $0.00, while SZLSF trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCLC currently has a P/E ratio of N/A, whereas SZLSF's P/E ratio is -0.16. In terms of profitability, HCLC's ROE is +0.11%, compared to SZLSF's ROE of +0.13%. Regarding short-term risk, HCLC and SZLSF have similar daily volatility (0.00).Check SZLSF's competition here
HCLC vs IDTA Comparison August 2025
HCLC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCLC stands at 74K. In comparison, IDTA has a market cap of 2M. Regarding current trading prices, HCLC is priced at $0.00, while IDTA trades at $0.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCLC currently has a P/E ratio of N/A, whereas IDTA's P/E ratio is 4.88. In terms of profitability, HCLC's ROE is +0.11%, compared to IDTA's ROE of +0.04%. Regarding short-term risk, HCLC and IDTA have similar daily volatility (0.00).Check IDTA's competition here
HCLC vs ICBU Comparison August 2025
HCLC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCLC stands at 74K. In comparison, ICBU has a market cap of 1.9M. Regarding current trading prices, HCLC is priced at $0.00, while ICBU trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCLC currently has a P/E ratio of N/A, whereas ICBU's P/E ratio is N/A. In terms of profitability, HCLC's ROE is +0.11%, compared to ICBU's ROE of +0.70%. Regarding short-term risk, HCLC is less volatile compared to ICBU. This indicates potentially lower risk in terms of short-term price fluctuations for HCLC.Check ICBU's competition here
HCLC vs IVRO Comparison August 2025
HCLC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCLC stands at 74K. In comparison, IVRO has a market cap of 1.8M. Regarding current trading prices, HCLC is priced at $0.00, while IVRO trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCLC currently has a P/E ratio of N/A, whereas IVRO's P/E ratio is -0.77. In terms of profitability, HCLC's ROE is +0.11%, compared to IVRO's ROE of +0.08%. Regarding short-term risk, HCLC and IVRO have similar daily volatility (0.00).Check IVRO's competition here
HCLC vs NSTM Comparison August 2025
HCLC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCLC stands at 74K. In comparison, NSTM has a market cap of 1.2M. Regarding current trading prices, HCLC is priced at $0.00, while NSTM trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCLC currently has a P/E ratio of N/A, whereas NSTM's P/E ratio is -0.42. In terms of profitability, HCLC's ROE is +0.11%, compared to NSTM's ROE of +1.28%. Regarding short-term risk, HCLC and NSTM have similar daily volatility (0.00).Check NSTM's competition here
HCLC vs DIGP Comparison August 2025
HCLC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCLC stands at 74K. In comparison, DIGP has a market cap of 1.1M. Regarding current trading prices, HCLC is priced at $0.00, while DIGP trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCLC currently has a P/E ratio of N/A, whereas DIGP's P/E ratio is -1.04. In terms of profitability, HCLC's ROE is +0.11%, compared to DIGP's ROE of +2.94%. Regarding short-term risk, HCLC is less volatile compared to DIGP. This indicates potentially lower risk in terms of short-term price fluctuations for HCLC.Check DIGP's competition here
HCLC vs EPGNF Comparison August 2025
HCLC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCLC stands at 74K. In comparison, EPGNF has a market cap of 982.2K. Regarding current trading prices, HCLC is priced at $0.00, while EPGNF trades at $1.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCLC currently has a P/E ratio of N/A, whereas EPGNF's P/E ratio is -0.05. In terms of profitability, HCLC's ROE is +0.11%, compared to EPGNF's ROE of -4.14%. Regarding short-term risk, HCLC and EPGNF have similar daily volatility (0.00).Check EPGNF's competition here
HCLC vs RSHN Comparison August 2025
HCLC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCLC stands at 74K. In comparison, RSHN has a market cap of 817.5K. Regarding current trading prices, HCLC is priced at $0.00, while RSHN trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCLC currently has a P/E ratio of N/A, whereas RSHN's P/E ratio is N/A. In terms of profitability, HCLC's ROE is +0.11%, compared to RSHN's ROE of -5.42%. Regarding short-term risk, HCLC and RSHN have similar daily volatility (0.00).Check RSHN's competition here
HCLC vs SCRSF Comparison August 2025
HCLC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCLC stands at 74K. In comparison, SCRSF has a market cap of 450.6K. Regarding current trading prices, HCLC is priced at $0.00, while SCRSF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCLC currently has a P/E ratio of N/A, whereas SCRSF's P/E ratio is -0.15. In terms of profitability, HCLC's ROE is +0.11%, compared to SCRSF's ROE of +1.97%. Regarding short-term risk, HCLC and SCRSF have similar daily volatility (0.00).Check SCRSF's competition here
HCLC vs TOMDF Comparison August 2025
HCLC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCLC stands at 74K. In comparison, TOMDF has a market cap of 140.8K. Regarding current trading prices, HCLC is priced at $0.00, while TOMDF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCLC currently has a P/E ratio of N/A, whereas TOMDF's P/E ratio is N/A. In terms of profitability, HCLC's ROE is +0.11%, compared to TOMDF's ROE of +0.84%. Regarding short-term risk, HCLC and TOMDF have similar daily volatility (0.00).Check TOMDF's competition here
HCLC vs NVTAQ Comparison August 2025
HCLC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCLC stands at 74K. In comparison, NVTAQ has a market cap of 85.9K. Regarding current trading prices, HCLC is priced at $0.00, while NVTAQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCLC currently has a P/E ratio of N/A, whereas NVTAQ's P/E ratio is -0.00. In terms of profitability, HCLC's ROE is +0.11%, compared to NVTAQ's ROE of +0.00%. Regarding short-term risk, HCLC is less volatile compared to NVTAQ. This indicates potentially lower risk in terms of short-term price fluctuations for HCLC.Check NVTAQ's competition here
HCLC vs ARYC Comparison August 2025
HCLC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCLC stands at 74K. In comparison, ARYC has a market cap of 79.3K. Regarding current trading prices, HCLC is priced at $0.00, while ARYC trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCLC currently has a P/E ratio of N/A, whereas ARYC's P/E ratio is N/A. In terms of profitability, HCLC's ROE is +0.11%, compared to ARYC's ROE of +0.55%. Regarding short-term risk, HCLC and ARYC have similar daily volatility (0.00).Check ARYC's competition here
HCLC vs OPGX Comparison August 2025
HCLC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCLC stands at 74K. In comparison, OPGX has a market cap of 55K. Regarding current trading prices, HCLC is priced at $0.00, while OPGX trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCLC currently has a P/E ratio of N/A, whereas OPGX's P/E ratio is -0.17. In terms of profitability, HCLC's ROE is +0.11%, compared to OPGX's ROE of +0.46%. Regarding short-term risk, HCLC and OPGX have similar daily volatility (0.00).Check OPGX's competition here
HCLC vs MEDVF Comparison August 2025
HCLC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCLC stands at 74K. In comparison, MEDVF has a market cap of 54K. Regarding current trading prices, HCLC is priced at $0.00, while MEDVF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCLC currently has a P/E ratio of N/A, whereas MEDVF's P/E ratio is -0.03. In terms of profitability, HCLC's ROE is +0.11%, compared to MEDVF's ROE of +2.13%. Regarding short-term risk, HCLC and MEDVF have similar daily volatility (0.00).Check MEDVF's competition here
HCLC vs RGDXQ Comparison August 2025
HCLC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCLC stands at 74K. In comparison, RGDXQ has a market cap of 38.8K. Regarding current trading prices, HCLC is priced at $0.00, while RGDXQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCLC currently has a P/E ratio of N/A, whereas RGDXQ's P/E ratio is N/A. In terms of profitability, HCLC's ROE is +0.11%, compared to RGDXQ's ROE of -1.27%. Regarding short-term risk, HCLC and RGDXQ have similar daily volatility (0.00).Check RGDXQ's competition here
HCLC vs CHHL Comparison August 2025
HCLC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCLC stands at 74K. In comparison, CHHL has a market cap of 37.3K. Regarding current trading prices, HCLC is priced at $0.00, while CHHL trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCLC currently has a P/E ratio of N/A, whereas CHHL's P/E ratio is N/A. In terms of profitability, HCLC's ROE is +0.11%, compared to CHHL's ROE of +0.00%. Regarding short-term risk, HCLC and CHHL have similar daily volatility (0.00).Check CHHL's competition here
HCLC vs MEDD Comparison August 2025
HCLC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCLC stands at 74K. In comparison, MEDD has a market cap of 31.9K. Regarding current trading prices, HCLC is priced at $0.00, while MEDD trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCLC currently has a P/E ratio of N/A, whereas MEDD's P/E ratio is -0.01. In terms of profitability, HCLC's ROE is +0.11%, compared to MEDD's ROE of +0.74%. Regarding short-term risk, HCLC and MEDD have similar daily volatility (0.00).Check MEDD's competition here
HCLC vs IHTI Comparison August 2025
HCLC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCLC stands at 74K. In comparison, IHTI has a market cap of 28.5K. Regarding current trading prices, HCLC is priced at $0.00, while IHTI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCLC currently has a P/E ratio of N/A, whereas IHTI's P/E ratio is N/A. In terms of profitability, HCLC's ROE is +0.11%, compared to IHTI's ROE of +0.00%. Regarding short-term risk, HCLC and IHTI have similar daily volatility (0.00).Check IHTI's competition here
HCLC vs CGNH Comparison August 2025
HCLC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCLC stands at 74K. In comparison, CGNH has a market cap of 12K. Regarding current trading prices, HCLC is priced at $0.00, while CGNH trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCLC currently has a P/E ratio of N/A, whereas CGNH's P/E ratio is N/A. In terms of profitability, HCLC's ROE is +0.11%, compared to CGNH's ROE of +1.41%. Regarding short-term risk, HCLC and CGNH have similar daily volatility (0.00).Check CGNH's competition here
HCLC vs ABMC Comparison August 2025
HCLC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCLC stands at 74K. In comparison, ABMC has a market cap of 4.8K. Regarding current trading prices, HCLC is priced at $0.00, while ABMC trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCLC currently has a P/E ratio of N/A, whereas ABMC's P/E ratio is 0.01. In terms of profitability, HCLC's ROE is +0.11%, compared to ABMC's ROE of +0.86%. Regarding short-term risk, HCLC and ABMC have similar daily volatility (0.00).Check ABMC's competition here
HCLC vs CYPS Comparison August 2025
HCLC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCLC stands at 74K. In comparison, CYPS has a market cap of 4.1K. Regarding current trading prices, HCLC is priced at $0.00, while CYPS trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCLC currently has a P/E ratio of N/A, whereas CYPS's P/E ratio is N/A. In terms of profitability, HCLC's ROE is +0.11%, compared to CYPS's ROE of N/A. Regarding short-term risk, HCLC and CYPS have similar daily volatility (0.00).Check CYPS's competition here
HCLC vs DMTKQ Comparison August 2025
HCLC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCLC stands at 74K. In comparison, DMTKQ has a market cap of 3.5K. Regarding current trading prices, HCLC is priced at $0.00, while DMTKQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCLC currently has a P/E ratio of N/A, whereas DMTKQ's P/E ratio is N/A. In terms of profitability, HCLC's ROE is +0.11%, compared to DMTKQ's ROE of -1.06%. Regarding short-term risk, HCLC and DMTKQ have similar daily volatility (0.00).Check DMTKQ's competition here
HCLC vs GWHP Comparison August 2025
HCLC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCLC stands at 74K. In comparison, GWHP has a market cap of 1.3K. Regarding current trading prices, HCLC is priced at $0.00, while GWHP trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCLC currently has a P/E ratio of N/A, whereas GWHP's P/E ratio is -0.00. In terms of profitability, HCLC's ROE is +0.11%, compared to GWHP's ROE of +0.00%. Regarding short-term risk, HCLC is less volatile compared to GWHP. This indicates potentially lower risk in terms of short-term price fluctuations for HCLC.Check GWHP's competition here
HCLC vs ROSGQ Comparison August 2025
HCLC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCLC stands at 74K. In comparison, ROSGQ has a market cap of 593. Regarding current trading prices, HCLC is priced at $0.00, while ROSGQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCLC currently has a P/E ratio of N/A, whereas ROSGQ's P/E ratio is N/A. In terms of profitability, HCLC's ROE is +0.11%, compared to ROSGQ's ROE of -1.35%. Regarding short-term risk, HCLC and ROSGQ have similar daily volatility (0.00).Check ROSGQ's competition here
HCLC vs BIOCQ Comparison August 2025
HCLC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCLC stands at 74K. In comparison, BIOCQ has a market cap of 263. Regarding current trading prices, HCLC is priced at $0.00, while BIOCQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCLC currently has a P/E ratio of N/A, whereas BIOCQ's P/E ratio is N/A. In terms of profitability, HCLC's ROE is +0.11%, compared to BIOCQ's ROE of -1.38%. Regarding short-term risk, HCLC and BIOCQ have similar daily volatility (0.00).Check BIOCQ's competition here
HCLC vs HTGMQ Comparison August 2025
HCLC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCLC stands at 74K. In comparison, HTGMQ has a market cap of 221. Regarding current trading prices, HCLC is priced at $0.00, while HTGMQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCLC currently has a P/E ratio of N/A, whereas HTGMQ's P/E ratio is N/A. In terms of profitability, HCLC's ROE is +0.11%, compared to HTGMQ's ROE of -2.73%. Regarding short-term risk, HCLC and HTGMQ have similar daily volatility (0.00).Check HTGMQ's competition here
HCLC vs MRPS Comparison August 2025
HCLC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCLC stands at 74K. In comparison, MRPS has a market cap of 0. Regarding current trading prices, HCLC is priced at $0.00, while MRPS trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCLC currently has a P/E ratio of N/A, whereas MRPS's P/E ratio is N/A. In terms of profitability, HCLC's ROE is +0.11%, compared to MRPS's ROE of N/A. Regarding short-term risk, HCLC and MRPS have similar daily volatility (0.00).Check MRPS's competition here
HCLC vs AGHC Comparison August 2025
HCLC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCLC stands at 74K. In comparison, AGHC has a market cap of 0. Regarding current trading prices, HCLC is priced at $0.00, while AGHC trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCLC currently has a P/E ratio of N/A, whereas AGHC's P/E ratio is N/A. In terms of profitability, HCLC's ROE is +0.11%, compared to AGHC's ROE of +2.90%. Regarding short-term risk, HCLC and AGHC have similar daily volatility (0.00).Check AGHC's competition here
HCLC vs BGNX Comparison August 2025
HCLC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCLC stands at 74K. In comparison, BGNX has a market cap of 0. Regarding current trading prices, HCLC is priced at $0.00, while BGNX trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCLC currently has a P/E ratio of N/A, whereas BGNX's P/E ratio is N/A. In terms of profitability, HCLC's ROE is +0.11%, compared to BGNX's ROE of N/A. Regarding short-term risk, HCLC and BGNX have similar daily volatility (0.00).Check BGNX's competition here
HCLC vs EPGNY Comparison August 2025
HCLC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCLC stands at 74K. In comparison, EPGNY has a market cap of 0. Regarding current trading prices, HCLC is priced at $0.00, while EPGNY trades at $2.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCLC currently has a P/E ratio of N/A, whereas EPGNY's P/E ratio is -1.60. In terms of profitability, HCLC's ROE is +0.11%, compared to EPGNY's ROE of -0.19%. Regarding short-term risk, HCLC and EPGNY have similar daily volatility (0.00).Check EPGNY's competition here